A phase 3 study of the fixed dose combination (FDC) tablets of bemnifosbuvir and ruzasvir
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Bemnifosbuvir/Ruzasvir (Primary) ; Sofosbuvir/velpatasvir
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- 17 Jan 2025 New trial record